Biotechnology News and Research

RSS

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

HHS awards CTI $977,917 in grants under Therapeutic Discovery Tax Credit program

Cell Therapeutics, Inc. today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The program targets projects that show potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs and advance the goal of curing cancer.

2 Nov 2010

PAREXEL first quarter revenue increases 13.9% to $295.8 million

PAREXEL International Corporation today announced its financial results for the first quarter ended September 30, 2010.

From Parexel 2 Nov 2010

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.

1 Nov 2010

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia

1 Nov 2010

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced its financial results for the quarter ended September 30, 2010.

1 Nov 2010

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.

1 Nov 2010

Cato Research selects BioClinica's clinical trial management system

BioClinica®, Inc.,, a global provider of clinical trial management solutions, today announced a new agreement with Cato Research Ltd., a full-service contract research organization. Cato Research selected BioClinica's clinical trial management system (CTMS) platform in its search for a best-in-class solution to better serve its growing worldwide client base.

From Clario 1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Vascular Pathways closes $14 million Series B equity financing round

Vascular Pathways Inc., a privately held medical device company with a breakthrough product for peripheral intravenous access, today announced that the company has closed a Series B preferred equity financing round of $14 million with premier venture capital firms active in medical technology.

1 Nov 2010

Life Technologies announces launch of new sequencer to deliver genomic data

Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.

1 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Clinical Data, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pulmonary arterial hypertension (PAH) to PRX-8066, the Company's selective serotonin 2B (5-HT2B) receptor antagonist.

1 Nov 2010

Global Genes Project launches new campaign to create awareness about rare diseases

The Global Genes Project, a non-profit advocacy organization that aims to raise awareness about the prevalence of rare diseases worldwide, today launched the 7,000 Bracelets for Hope campaign. The 7,000 Bracelets for Hope campaign is designed to draw attention to an estimated 7,000 different chronic, life-threatening and fatal rare diseases and disorders affecting approximately 30 million Americans and millions more globally.

1 Nov 2010

Acorda reports net income of $12.4 million for third quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2010.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

Biotechnology News and Research

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

HHS awards CTI $977,917 in grants under Therapeutic Discovery Tax Credit program

PAREXEL first quarter revenue increases 13.9% to $295.8 million

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

Cato Research selects BioClinica's clinical trial management system

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Vascular Pathways closes $14 million Series B equity financing round

Life Technologies announces launch of new sequencer to deliver genomic data

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Global Genes Project launches new campaign to create awareness about rare diseases

Acorda reports net income of $12.4 million for third quarter 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Mechanism of rogue cell killer discovered

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News